
TNL Mediagene Co-Hosts the 2025 Generative AI Conference, Expands Presence in AI Ecosystem in Asia
NEW YORK and TOKYO, May 29, 2025 /PRNewswire/ — TNL Mediagene (Nasdaq: TNMG) (the 'Company'), a Tokyo-based next-generation digital media and data group in Asia, co-hosted the 2025 Generative AI Conference on May 23-24, the most influential AI event in Asia, with participants from Malaysia, Singapore, Hong Kong and Japan. The event drew approximately 1,000 attendees and 2,000 virtual attendees post-event, and expands the Company's presence in the AI ecosystem in Asia.
The 2025 Generative AI Conference is Taiwan's premier AI event, bringing together the public, developers, AI-focused start-ups, vendors and press. Co-organized by Muyueh Lee, the curator of the Generative AI Conference and TNL Mediagene, the two-day conference featured a split agenda including the Generative AI Developers Conference on May 23, followed by the Generative AI Conference on May 24. Event sponsors included leading tech companies NVIDIA and Appier, among others.
The 2025 Generative AI Conference was not only a technology event, but also a collaborative arena for professionals across industries to co-create the future of AI applications.
As the event's key media and strategic partner, the Company leveraged its media platforms INSIDE, The News Lens, Business Yee, and Cool3c to provide extensive coverage and insights before, during and after the event. The conference included brand experience booths and expert forums, offering a space for dialogue between local and global AI pioneers and is one of Asia-Pacific's premier AI exchange platforms.
'The 2025 Generative AI Conference was a big success for us. Co-hosting this event was a key milestone for the Company, both on a personal level and from a business perspective. The event provided great visibility for our brand, essentially recognizing us as one of the key players in AI in Taiwan and Asia more broadly, and allowed us to get in front of a large group of innovators, industry participants and businesses for potential future follow-on business opportunities' Co-Founder & CEO Joey Chung said.
By gathering global experts and Taiwan's top enterprises, the 2025 Generative AI Conference also functioned as a potential launchpad for partnerships, innovation, and practical applications of generative AI.
The event focused on Generative AI broadly and highlighted various use cases for the technology including integrating AI into everyday processes in retail, process automation, AI Agents, AI coding, AI experience design and AI-based content creation, among others.
'Generative AI is a game-changer in our industry, especially in terms of content creation and content optimization. We actively use AI as part of our multilingualization strategies where we basically take entire media properties with content native to one geography and push it to new geographies with AI-based translation to expand readership. We are finding that this process works well enough that in many cases the readers in additional markets may not even realize that the media originated from a different language market. We have also found that we have been able to take a lot of cost out of our business and enhance profitability through AI, so that is also another AI use case for us and something we are very focused on as well.'
'On a more strategic level, we are also always selectively enhancing our offering through technology M&A when we can find the right supplementary business at a good price, with AI targets being a key focal point. The opportunity to get our name out there in a high-visibility AI-centric forum where we can meet a lot of founders is always a big plus for us' Joey concluded.
About TNL Mediagene
Headquartered in Tokyo, TNL Mediagene was formed in May 2023 through the merger of Taiwan's The News Lens Co., Ltd. and Japan's Mediagene Inc., two of the region's leading independent digital media groups. The company's operations span original and licensed media brands in Japanese, Chinese, and English, covering topics such as news, business, technology, science, food, sports, and lifestyle. It also offers AI-driven advertising services, marketing technology platforms, e-commerce, and innovative solutions tailored to the needs of advertising agencies. Known for its political neutrality, appeal to younger audiences, and high-quality content, TNL Mediagene has approximately 500 employees across Asia, with offices in Japan, Taiwan, and Hong Kong.
https://www.tnlmediagene.com/
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to TNL Mediagene. Forward-looking statements generally relate to future events or TNL Mediagene's future financial or operating performance. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements in this communication include statements about TNL Mediagene's future business plan and growth strategies and statements by TNL Mediagene's CEO. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for TNL Mediagene to predict these events or how they may affect TNL Mediagene. In addition, risks and uncertainties are described in TNL Mediagene's filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. TNL Mediagene cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that TNL Mediagene presently does not know or that TNL Mediagene currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by TNL Mediagene, its directors, officers or employees or any other person. Except as required by applicable law, TNL Mediagene does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of TNL Mediagene as of any date subsequent to the date of this communication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
2 hours ago
- Malaysian Reserve
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme 'Empowering the Potential of ctDNA-MRD,' 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. 'While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,' said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. 'Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.' 'K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. 'This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@


Malaysian Reserve
4 hours ago
- Malaysian Reserve
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR
DELRAY BEACH, Fla., May 30, 2025 /PRNewswire/ — The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine. The rising number of cancer cases worldwide and increased funding for various types of research are other important factors propelling the market's growth. Moreover, advances in omics technologies, including genomics and proteomics, are now enabling the development of more sophisticated tests based on biomarkers. Many companies are now targeting new markets such as the Asia Pacific region, where there is a high demand for targeted diagnostics, thus creating new opportunities for biomarker-driven solutions. Download PDF Brochure: Browse in-depth TOC on 'Biomarkers Market' 700 – Tables54 – Figures510 – Pages By offering, the biomarkers market is categorized into consumables, services, and software. Consumables are further sub segmented into assay kits, reagents & chemicals, and columns & filters. The consumables segment accounted for the largest share of the global biomarkers market in 2024. The large share of consumables is due to the high and recurring demand for assay kits, reagents, and other consumables in biomarker-based research, diagnostics, and validation workflows, which ensures continuous usage across laboratories and clinical settings. Additionally, the growing number of biomarker-based studies and clinical trials has driven the need for reliable, high-throughput consumables that support reproducibility and scalability. Moreover, the increasing adoption of multiplex assay platforms, which require specialized consumables to detect multiple biomarkers from limited sample volumes, also supports the large share of the consumables segment. By type, the biomarkers market is categorized into safety, efficacy, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers. The safety biomarkers segment held the largest share in the biomarkers market in 2024. This can be attributed to the use of safety biomarkers in drug development to assess toxicity and identify potential adverse effects early in the development process. Regulatory agencies increasingly require safety biomarkers to ensure drug candidates meet safety standards before advancing to later stages of clinical trials. Additionally, pharmaceutical companies are investing in safety biomarker strategies to reduce the risk of late-stage failures and improve decision-making during preclinical and early clinical phases. By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030. This growth is supported by this technology's high sensitivity, cost-effectiveness, and broad applicability in detecting and quantifying genetic material. Companies can utilize this growth by expanding PCR-based test offerings, developing multiplex PCR kits, and integrating PCR platforms into biomarker-based diagnostics and companion tests. While PCR is expected to lead in growth, companies can also benefit from incorporating other technologies, such as NGS and MS, to support comprehensive biomarker analysis, particularly where high-throughput sequencing or protein-level insights are required. By geography, the biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2024, North America held the largest share in the biomarkers market due to its well-established healthcare infrastructure, high research and development spending, and strong presence of leading pharmaceutical and biotechnology companies. The region has a high adoption rate of advanced technologies, including next-generation sequencing and companion diagnostics, which support biomarker discovery and application across clinical and research settings. Additionally, favorable regulatory frameworks, availability of funding from government and private sources, and a growing focus on precision medicine have further driven the use of biomarkers. The increasing burden of chronic diseases such as cancer and cardiovascular conditions has also contributed to sustained demand for biomarker-based diagnostics and therapies in the region. Request Sample Pages : Key players in the biomarkers market include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), and JSR Corporation (Japan). The market includes many other prominent companies and competitive startups/SMEs. F. Hoffmann-La Roche Ltd (Switzerland): F. Hoffmann-La Roche Ltd is a major player in the global biomarker market, leveraging its integrated diagnostics-pharmaceutical business model, strong geographical presence, and ongoing innovation. The company operates in two segments: Diagnostics and Pharmaceuticals, with the Diagnostics division encompassing Core Lab, Molecular Lab, Pathology Lab, Point of Care, and Diabetes Care. These divisions provide biomarker-based assays, digital platforms, and companion diagnostics for applications in oncology, cardiology, neurology, infectious diseases, and diabetes. In 2023, Roche's Diagnostics division processed over 29 billion tests across more than 100,000 platforms, reflecting strong global demand. The company launched over 20 diagnostic assays between 2022 and May 2025, including the FDA-approved VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer. Roche also actively pursues partnerships, such as collaborations with PathAI for AI-based pathology algorithms and with Neuron23 to utilize digital biomarkers in Parkinson's disease trials. Roche's integration of diagnostic development, test delivery, and data platforms, along with its global reach and AI-enabled R&D, enhances its leadership in the biomarker market. Merck KGaA (Germany) Merck KGaA is a major player in the biomarker market through its Life Science segment, which provides biomarker assays, consumables, software, and services for research and diagnostics. The Science & Lab Solutions division focuses on biomarker discovery, validation, and analysis. With a global presence and subsidiaries like EMD Millipore Corporation and Merck Biosciences AG, Merck has strengthened its position through strategic partnerships. In January 2025, it collaborated with Qpentions Labworks to automate assay workflows with the Flex robotic workstation, enhancing protein sample preparation. Additionally, in June 2024, Merck partnered with the Michael J. Fox Foundation to support the SMCXPRQ immunoassay platform for detecting low-abundance biomarkers related to early Parkinson's disease. This focus on automation and disease-specific advancements highlights Merck's significant role in the global biomarker market. For more information, Inquire Now! Related Reports: Cancer Biomarkers Market Cardiac Marker Testing Market Cancer Profiling Market Companion Diagnostics Market PCR Technologies Market Get access to the latest updates on Biomarkers Companies and Biomarkers Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:

The Star
5 hours ago
- The Star
S&P 500 ends little changed in volatile session
The Dow rose 54.34 points, or 0.13%, to 42,270.07. The S&P 500 lost 0.48 points, or 0.01%, at 5,911.69 and the Nasdaq fell 62.11 points, or 0.32%, to 19,113.77.